These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ: ANIP ) reported upbeat earnings for the second quarter on Friday.

The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share.

The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.

ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion. “In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing.

The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.” ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.

These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.

Canaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.

Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.

Considering buying ANIP stock? Here’s what analysts think: Photo via Shutterstock